D-domain (triangular binding site)
Use this icon in our BioRender software along with 1000s of others. Create your next scientific figure in minutes!
SIGN UP FREE[{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd9a/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd9a/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd99/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd99/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd98/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd98/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd97/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd97/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd96/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd96/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd95/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd95/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd94/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd94/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd93/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd93/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd92/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd92/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd91/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd91/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd90/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd90/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8f/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8f/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8e/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8e/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8d/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8d/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8c/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8c/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8b/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8b/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd8a/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd8a/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd89/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd89/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd88/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd88/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd87/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd87/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd86/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd86/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd85/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd85/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd84/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd84/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd83/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd83/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd82/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd82/d-domain-triangular-binding-site.png"},{"image":"https://icons.biorender.com/w75xh75/63dd2a6452f9f70020b4cd81/d-domain-triangular-binding-site.png","waterMarkImage":"https://icons.biorender.com/w550xh620/63dd2a6452f9f70020b4cd81/d-domain-triangular-binding-site.png"}]
Keywords
D-domain,d domain,binding site,generic protein,Arcellx,ddCAR,ARC-SparX,sparx,protein,domain,binding domain,antigen binding,antigen receptor,recognition,CAR-T cell therapy,chimeric antigen receptor,synthetic,binding agent,synthetic binding agent,biotechnology,target-binding domain,cell therapy,immunotherapy,immune therapy,cancer treatment,cancer research,oncology,target specificity,binding affinity,active site,space-filled protein,space-filling,molecule,generic molecule,macromolecule,triangular,triangle
.png)
.svg)
